Aurorix Dosage/Direction for Use

Standard Dosage: Depressive syndromes: The recommended dose range of moclobemide is 300 and 600 mg of moclobemide (equivalent of 2 to 4 film-coated tablets Aurorix 150mg or 1 to 2 film-coated tablets Aurorix 300mg). Usually, this dosage is given in two to three divided doses after the meal.
The initial dose is 300 mg of moclobemide per day (equivalent of 2 film-coated tablets Aurorix 150 mg or 1 film-coated tablet Aurorix 300 mg). In patients with severe depression, this dose may be increased to 600 mg of moclobemide daily (equivalent of 4 film-coated tablets Aurorix 150mg or 2 film-coated tablets Aurorix 300mg).
However, the dose should not be raised until after the first week, as bioavailability increases during this period (see Pharmacology: Pharmacokinetics: Pharmacokinetics in special populations under Actions).
Note: The dose of moclobemide does not need to be specially adjusted in elderly patients or patients with reduced renal function.
When hepatic metabolism is severely impaired by hepatic disease or by a medicine that inhibits the activity of certain liver enzymes (microsomal mono-oxygenase) - such as cimetidine, the daily dose of moclobemide should be reduced to half or one third to reach the usual plasma level (see Pharmacology: Pharmacokinetics: Pharmacokinetics in special populations under Actions and Interactions).
With appropriate caution, a patient can be switched from moclobemide to tricyclic or other antidepressants without observing any waiting period, i.e. from one day to the other.
When switching a patient from other antidepressants to moclobemide, a washout phase is recommended the duration of which depends on the half-life of the previously administered antidepressant.
As a general rule, a free interval of 14 days is recommended when switching a patient from an irreversible MAO inhibitor (such as phenelzine, tranylcypromine) to moclobemide.
After end of treatment with selective serotonin reuptake inhibitors (SSRIs) and before treatment with moclobemide is initiated, a washout phase lasting up to 4 to 5 times the half-life of the active substance and its metabolites is recommended.
When switching to moclobemide, the dose should not exceed 300 mg/day during the first week of treatment.
Special Dosage Instructions: The dose should be taken after a meal with some liquid.
Treatment should continue for at least 4-6 weeks in order to assess the efficacy of the medicine.
There is no limit with regard to the duration of treatment.